{"id":9324,"date":"2025-05-22T13:01:29","date_gmt":"2025-05-22T18:01:29","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&#038;p=9324"},"modified":"2025-06-26T15:11:30","modified_gmt":"2025-06-26T20:11:30","slug":"relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/pt\/publicaciones\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/","title":{"rendered":"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) &#8211; PORT"},"content":{"rendered":"<p>O Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI), elaborado pela Pugatch Consilium, analisa o ambiente de investimento em sa\u00fade na Am\u00e9rica Latina. A regi\u00e3o obteve uma pontua\u00e7\u00e3o m\u00e9dia de 59%, ficando atr\u00e1s de outros mercados emergentes altamente competitivos, como Singapura e Israel. No ranking regional, Costa Rica, Chile e M\u00e9xico se destacam como os pa\u00edses com as melhores condi\u00e7\u00f5es para atrair investimentos biofarmac\u00eauticos.<\/p>\n\n\n\n<p>O estudo identifica avan\u00e7os importantes nas capacidades cient\u00edficas e regulat\u00f3rias em alguns pa\u00edses, mas tamb\u00e9m ressalta desafios persistentes no acesso ao mercado e na prote\u00e7\u00e3o eficaz da propriedade intelectual. Apesar dessas lacunas, o relat\u00f3rio \u00e9 claro: a Am\u00e9rica Latina tem uma oportunidade estrat\u00e9gica de se posicionar como um polo de inova\u00e7\u00e3o, se adotar pol\u00edticas p\u00fablicas mais previs\u00edveis, fortalecer seus marcos regulat\u00f3rios e promover uma colabora\u00e7\u00e3o mais estreita entre os setores p\u00fablico, privado e acad\u00eamico.<\/p>\n\n\n\n<p><a href=\"https:\/\/fifarma.org\/wp-content\/uploads\/2025\/05\/Biopharmaceutical-Competitiveness-Investment-Report-BCI-2025-PORT.pdf\">Ver documento<\/a><\/p>\n\n\n\n<p><\/p>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"author":26,"parent":0,"template":"","ano":[],"idioma":[],"etiquetas-publicacion":[57,157,156],"categoria-publicacion":[29],"class_list":["post-9324","publicaciones","type-publicaciones","status-publish","hentry","etiquetas-publicacion-ecosistemas-de-innovacion","etiquetas-publicacion-health","etiquetas-publicacion-latam","categoria-publicacion-reporte"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.7 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) - PORT - FIFARMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/pt\/publicacoes\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) - PORT\" \/>\n<meta property=\"og:description\" content=\"O Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI), elaborado pela Pugatch Consilium, analisa o ambiente de investimento em sa\u00fade na Am\u00e9rica Latina. A regi\u00e3o obteve uma pontua\u00e7\u00e3o m\u00e9dia de 59%, ficando atr\u00e1s de outros mercados emergentes altamente competitivos, como Singapura e Israel. No ranking regional, Costa Rica, Chile e M\u00e9xico se destacam como os [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/pt\/publicacoes\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-26T20:11:30+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\\\/\",\"name\":\"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) - PORT - FIFARMA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2025-05-22T18:01:29+00:00\",\"dateModified\":\"2025-06-26T20:11:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) &#8211; PORT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) - PORT - FIFARMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/pt\/publicacoes\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/","og_locale":"pt_BR","og_type":"article","og_title":"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) - PORT","og_description":"O Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI), elaborado pela Pugatch Consilium, analisa o ambiente de investimento em sa\u00fade na Am\u00e9rica Latina. A regi\u00e3o obteve uma pontua\u00e7\u00e3o m\u00e9dia de 59%, ficando atr\u00e1s de outros mercados emergentes altamente competitivos, como Singapura e Israel. No ranking regional, Costa Rica, Chile e M\u00e9xico se destacam como os [&hellip;]","og_url":"https:\/\/fifarma.org\/pt\/publicacoes\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/","og_site_name":"FIFARMA","article_modified_time":"2025-06-26T20:11:30+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/","url":"https:\/\/fifarma.org\/publicaciones\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/","name":"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) - PORT - FIFARMA","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2025-05-22T18:01:29+00:00","dateModified":"2025-06-26T20:11:30+00:00","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/relatorio-de-competitividade-e-investimento-biofarmaceutico-2025-bci\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"Relat\u00f3rio de Competitividade e Investimento Biofarmac\u00eautico 2025 (BCI) &#8211; PORT"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Federa\u00e7\u00e3o Latino-Americana da Ind\u00fastria Farmac\u00eautica","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones\/9324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/users\/26"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/media?parent=9324"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/ano?post=9324"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/idioma?post=9324"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/etiquetas-publicacion?post=9324"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/categoria-publicacion?post=9324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}